NCT03991884View on ClinicalTrials.gov

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

October 20, 2022

Study Completion Date

June 28, 2023

Conditions
Recurrent B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic LymphomaRefractory B Acute Lymphoblastic LeukemiaRefractory B Lymphoblastic Lymphoma
Interventions
DRUG

Etoposide

Given IV

DRUG

Doxorubicin

Given IV

DRUG

Vincristine

Given IV

DRUG

Prednisone

Given PO or IV

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Inotuzumab Ozogamicin

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Washington

OTHER

NCT03991884 - Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter